<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C36A27E4-704A-43AC-9851-243DC6578E01"><gtr:id>C36A27E4-704A-43AC-9851-243DC6578E01</gtr:id><gtr:name>PulmonX Ltd</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C36A27E4-704A-43AC-9851-243DC6578E01"><gtr:id>C36A27E4-704A-43AC-9851-243DC6578E01</gtr:id><gtr:name>PulmonX Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/40B8E136-D92C-4B9B-A822-762445BA707C"><gtr:id>40B8E136-D92C-4B9B-A822-762445BA707C</gtr:id><gtr:firstName>Nicholas</gtr:firstName><gtr:otherNames>S</gtr:otherNames><gtr:surname>Hopkinson</gtr:surname><gtr:orcidId>0000-0003-3235-0454</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_12032"><gtr:id>24954058-F2D2-4A2D-BCEE-1240A8995427</gtr:id><gtr:title>Bronchoscopic lung volume reduction with endobronchial valves for patients with heterogeneous emphysema and intact interlobar fissures - a proof of concept study</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_12032</gtr:grantReference><gtr:abstractText>Chronic obstructive pulmonary disease (COPD) is a common lung condition usually caused by smoking. It is a mixture of bronchitis (airway damage) and emphysema (damage to the lung tissue itself). In emphysema the lungs become baggy and full of holes and the sufferer is unable to breathe out fully ? this is called ?gas trapping?. This causes breathlessness, exercise limitation, poor quality of life. Although tablet and inhaled therapy provide some benefit many people are still very limited by their disease. A different approach is to use a fibreoptic camera (bronchoscope) to place valves into the airways of the lung to prevent air from entering the most over-inflated part. If the most damaged area of lung can be made to collapse this way it makes more space for the remaining healthier lung to function. Unfortunately, in many patients lung destruction breaks down the barriers (fissures) between the target lobe and adjacent lung which allows to ?get round behind? the valves so that the lung does not collapse. Because of this, in a multicentre study of valve placement recently published, the improvements seen in the whole group were fairly small. Looking back at the data it appeared that the response in those who had intact fissures was much larger. The aim of our study is to see whether by selecting only the people we would expect to have a good response in advance we can get a reliable and clinically meaningful response to valve treatment. We will conduct a double blind, randomised controlled trial in 50 emphysema patients with intact interlobar fissures, the pattern that is most likely to respond. Half will have valves placed to occlude the worst affected lobe of their lungs and half will have a bronchoscopy performed but no valves placed ? they will not know which treatment arm they are in. ?Sham? bronchoscopy is acceptable to patients and has been used safely in other trials. Response to treatment will be assessed 90 days post procedure. The primary outcome will be improvement in lung function but we will also look at changes in exercise capacity and health related quality of life. The study will be performed at The Royal Brompton Hospital supported by the Imperial College Clinical Trials Unit. Our team have considerable experience in this area having published the first trial with these valves in COPD patients in The Lancet in 2003 and combining expertise in interventional bronchoscopy and physiological measurement. Support is requested for a research nurse or physiotherapist to coordinate the study, recruit patients and perform physiological measurements as well as for the NHS research costs of CT scans, lung function measurements and exercise testing and to cover patient transport costs and clinical trial unit support.</gtr:abstractText><gtr:technicalSummary>BACKGROUND - Patients with COPD often remain breathless despite optimum pharmacological therapy. Bronchoscopic lung volume reduction (BLVR) involves placing valves to occlude airways leading to the most affected area of lung, causing it to collapse and so improve operating lung volumes and exercise capacity. Response is highly variable, but our data suggest that where successful it may lead to a significant survival benefit. A multicentre trial (VENT) has confirmed that valve placement can improve lung function. Mean group benefits were modest because in many patients there is collateral ventilation between the target lobe and adjacent areas of lung meaning that the target area remains inflated. However, post hoc analysis of this trial suggested that the benefit in patients with intact interlobar fissures and correct valve placement was similar to that seen in lung volume reduction surgery (LVRS). HYPOTHESIS AND AIMS - The aim of this study is to establish whether an approach treating only the subgroup of patients with intact fissures and the most heterogeneous pattern of disease will lead to a large and consistent benefit. METHODS - A single centre, double-blind randomised controlled trial of BLVR aimed to achieve lobar occlusion in COPD, selecting only patients with heterogeneous emphysema and intact interlobar fissures. A control group who will receive a sham procedure (bronchoscopy without valve placement). Primary endpoint will be change in FEV1 90 days post-procedure. We will also measure lung volume changes, endurance exercise capacity with measurement of dynamic hyperinflation as well as health related quality of life and 6 minute walk distance. 50 patients will be enrolled to have 90% power to detect a 15% difference in FEV1 response between the two study arms. ECONOMIC BENEFIT - BLVR is significantly cheaper, with fewer complications than LVRS but a reliable estimate of benefit remains to be established. Confirming that a consistent, beneficial response can occur in a clearly defined subgroup of patients with COPD will be a significant step forward in management potentially leading to a reduction in long term health-care utilisation. THE TEAM ? The advanced COPD service at Royal Brompton Hospital, led by Dr Hopkinson has considerable expertise in the field of BLVR having published the first trial in The Lancet in 2003. Our multidisciplinary team receives both secondary and tertiary referrals for interventions including LVRS and transpleural airway bypass. The Clinical Trials and Evaluation Unit (CTEU), which is part of the Imperial College Clinical Trials Unit, will support the study. Professor Polkey leads the COPD consortium of the NIHR Respiratory BRU at Royal Brompton and Imperial College and Dr Pallav Shah is founding chair of the bronchoscopy advisory group for the British Thoracic Society and has enormous interventional bronchoscopy experience. Our patient representative, Allan Stone, is chair of our local British Lung Foundation Breathe Easy Group. Winston Banya an experienced statistician working with CTEU and the BRU will assist with analysis.</gtr:technicalSummary><gtr:fund><gtr:end>2014-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-02-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>247452</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>PulmonX Ltd</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>PulmonX-BeLieVeR-HIFi</gtr:description><gtr:id>0FE861A0-0370-4563-9152-573860423082</gtr:id><gtr:impact>Project still underway</gtr:impact><gtr:outcomeId>ZQ1GPMHQanc-1</gtr:outcomeId><gtr:partnerContribution>PulmonX provided free endobronchial valves for this project.</gtr:partnerContribution><gtr:piContribution>We developed a project to evaluate endobronchial valves in patietns with emphysema through NIHR/EME</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BLVR network</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>British Lung Foundation (BLF)</gtr:fundingOrg><gtr:id>8B77A0EC-BB2F-40CE-AD62-BB533490DE07</gtr:id><gtr:outcomeId>545cf5de6ecc96.31348177</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>349990</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Biomedical Research Centre</gtr:department><gtr:description>Research for Patient Benefit</gtr:description><gtr:end>2019-04-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>PB-PG-1014-35051</gtr:fundingRef><gtr:id>D12CAF1D-7325-455F-A97D-5977E3324A39</gtr:id><gtr:outcomeId>56d57649d819e8.06835039</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Trial of endobronchial valves for emphysema</gtr:description><gtr:id>69D511D7-ECFC-4103-B11D-58FE2A5E7AB6</gtr:id><gtr:impact>Trial still underway</gtr:impact><gtr:outcomeId>S9Mj84bQaVk</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>BeLieVeR-HIFi study</gtr:title><gtr:type>Therapeutic Intervention - Medical Devices</gtr:type><gtr:ukcrnIsctnId>ISRCTN04761234</gtr:ukcrnIsctnId><gtr:url>http://www.controlled-trials.com/ISRCTN04761234/Hopkinson</gtr:url><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>DE6773B6-63C6-4744-B859-923494278BA2</gtr:id><gtr:title>Effective Bronchoscopic Lung Volume Reduction Accelerates Exercise Oxygen Uptake Kinetics in Emphysema.</gtr:title><gtr:parentPublicationTitle>Chest</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b0fafd54ce0b2c071e347fd00f6972df"><gtr:id>b0fafd54ce0b2c071e347fd00f6972df</gtr:id><gtr:otherNames>Faisal A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0012-3692</gtr:issn><gtr:outcomeId>56c1dbc0472612.27580189</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D78D4919-9734-44F1-B81F-6F888517A672</gtr:id><gtr:title>Endobronchial valves for emphysema: an individual patient-level reanalysis of randomised controlled trials.</gtr:title><gtr:parentPublicationTitle>BMJ open respiratory research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/861fee8a65337d6dcf78bd1e58bb9709"><gtr:id>861fee8a65337d6dcf78bd1e58bb9709</gtr:id><gtr:otherNames>Klooster K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2052-4439</gtr:issn><gtr:outcomeId>5a1d85b49487a5.52905550</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7211BC0C-9255-48C2-AFE9-F9455CBADF89</gtr:id><gtr:title>Emphysema: time to say farewell to therapeutic nihilism.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1fd0d781391df8949eca239d817b95b2"><gtr:id>1fd0d781391df8949eca239d817b95b2</gtr:id><gtr:otherNames>Zoumot Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>545ceac99247f4.32444852</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F192FCA3-B5DA-47A7-B677-C16B7BAF401B</gtr:id><gtr:title>Attitudes and access to lung volume reduction surgery for COPD: a survey by the British Thoracic Society.</gtr:title><gtr:parentPublicationTitle>BMJ open respiratory research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d5473edd062a521adca91e09b29bb8dc"><gtr:id>d5473edd062a521adca91e09b29bb8dc</gtr:id><gtr:otherNames>McNulty W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2052-4439</gtr:issn><gtr:outcomeId>56c1dbc345bb17.61119080</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E952CB2C-F2DE-463C-B29D-133A690B144A</gtr:id><gtr:title>Patient experience of lung volume reduction procedures for emphysema: a qualitative service improvement project.</gtr:title><gtr:parentPublicationTitle>ERJ open research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4d7d873ddb485122ad2ce249963cb85e"><gtr:id>4d7d873ddb485122ad2ce249963cb85e</gtr:id><gtr:otherNames>Buttery S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2312-0541</gtr:issn><gtr:outcomeId>5a1d85b7625396.58762392</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56F5B79D-7B83-4880-AC08-72DB8573EAAE</gtr:id><gtr:title>Surgical approaches for lung volume reduction in emphysema.</gtr:title><gtr:parentPublicationTitle>Clinical medicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6296b4266e4f550f4b387140ab8da49e"><gtr:id>6296b4266e4f550f4b387140ab8da49e</gtr:id><gtr:otherNames>Clark SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1470-2118</gtr:issn><gtr:outcomeId>545ceac8d04145.08663378</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E0AC7C2-BC91-4954-8306-59F5B3AEEC1F</gtr:id><gtr:title>Lung Volume Reduction in Emphysema Improves Chest Wall Asynchrony.</gtr:title><gtr:parentPublicationTitle>Chest</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1fd0d781391df8949eca239d817b95b2"><gtr:id>1fd0d781391df8949eca239d817b95b2</gtr:id><gtr:otherNames>Zoumot Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0012-3692</gtr:issn><gtr:outcomeId>56c1dbc0141160.98488248</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3DCB20C-3233-437D-B8BE-5D24DE531037</gtr:id><gtr:title>Bronchoscopic lung volume reduction for emphysema: where next?</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/60b4b7993cf946d9d7f0e8486771b040"><gtr:id>60b4b7993cf946d9d7f0e8486771b040</gtr:id><gtr:otherNames>Shah PL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>pm_15341_21_22654002</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E22C9B28-8598-472D-BB70-36EDFCC34194</gtr:id><gtr:title>Endobronchial Valves as a Treatment for Emphysema. Moving out of the Shadow of Lung Volume Reduction Surgery.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9dc2453841bf7c98f36c11c861233e9b"><gtr:id>9dc2453841bf7c98f36c11c861233e9b</gtr:id><gtr:otherNames>Hopkinson NS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>5899c4d7777df6.59355333</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2EFB47E3-FD73-4AE1-8556-A7FF6DAAEB5F</gtr:id><gtr:title>Bronchoscopic lung volume reduction with endobronchial valves for patients with heterogeneous emphysema and intact interlobar fissures (the BeLieVeR-HIFi trial): study design and rationale.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8772bdefc0171096ff17c4c62ec90aca"><gtr:id>8772bdefc0171096ff17c4c62ec90aca</gtr:id><gtr:otherNames>Davey C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>545ceac88976c4.35489856</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E1436480-C429-48E5-A12F-99F588517796</gtr:id><gtr:title>An evaluation of factors associated with completion and benefit from pulmonary rehabilitation in COPD.</gtr:title><gtr:parentPublicationTitle>BMJ open respiratory research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b3fe007a7af88e80c69429116a32eb1d"><gtr:id>b3fe007a7af88e80c69429116a32eb1d</gtr:id><gtr:otherNames>Boutou AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2052-4439</gtr:issn><gtr:outcomeId>56c1dbc3198274.12021456</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>986AF893-55B9-4631-B353-8C0DA937111B</gtr:id><gtr:title>Endobronchial coils for severe emphysema are effective up to 12 months following treatment: medium term and cross-over results from a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1fd0d781391df8949eca239d817b95b2"><gtr:id>1fd0d781391df8949eca239d817b95b2</gtr:id><gtr:otherNames>Zoumot Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56c1dbc2947548.16553541</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF6E4AFE-C576-4F4F-B385-675277800622</gtr:id><gtr:title>Endobronchial valves for patients with heterogeneous emphysema and without interlobar collateral ventilation: open label treatment following the BeLieVeR-HIFi study.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1fd0d781391df8949eca239d817b95b2"><gtr:id>1fd0d781391df8949eca239d817b95b2</gtr:id><gtr:otherNames>Zoumot Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>5899c0e8488357.71737924</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>65196A3D-348E-426C-86BF-1D0E86ED896C</gtr:id><gtr:title>Bronchoscopic lung volume reduction with endobronchial valves for patients with heterogeneous emphysema and intact interlobar fissures (the BeLieVeR-HIFi study): a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8772bdefc0171096ff17c4c62ec90aca"><gtr:id>8772bdefc0171096ff17c4c62ec90aca</gtr:id><gtr:otherNames>Davey C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>56c1dbbfaf73c1.56041323</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A1DAACF6-2D07-42A5-9EF8-A1302C4576D6</gtr:id><gtr:title>The Impact of Homogeneous Versus Heterogeneous Emphysema on Dynamic Hyperinflation in Patients With Severe COPD Assessed for Lung Volume Reduction.</gtr:title><gtr:parentPublicationTitle>COPD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b3fe007a7af88e80c69429116a32eb1d"><gtr:id>b3fe007a7af88e80c69429116a32eb1d</gtr:id><gtr:otherNames>Boutou AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1541-2563</gtr:issn><gtr:outcomeId>56c1dbbeef5fc2.08757145</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF6BB960-C9E0-441D-9707-B48460DCEA7E</gtr:id><gtr:title>Survival after Endobronchial Valve Placement for Emphysema: A 10-Year Follow-up Study.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad2136661a4bbb47ee935ffabdae3fa1"><gtr:id>ad2136661a4bbb47ee935ffabdae3fa1</gtr:id><gtr:otherNames>Garner J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>5899c4d79a4413.32513185</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_12032</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>